Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

被引:6
|
作者
Zhang, Qiongwen [1 ,2 ]
He, Ping [3 ]
Tian, Tinglun [3 ]
Yan, Xi [3 ]
Huang, Juan [4 ]
Zhang, Zhang [5 ]
Zheng, Hong [3 ,6 ]
Zhong, Xiaorong [3 ,6 ]
Luo, Ting [3 ,6 ]
机构
[1] Sichuan Univ, Canc Ctr, West China Hosp, Dept Radiat Oncol,Dept Head & Neck Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Breast Dis Ctr, Canc Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Innovat Ctr Biotherapy, Multi Lab Breast Dis,State Key Lab Biotherapy,Natl, Chengdu, Peoples R China
关键词
HER2-positive breast cancer; real-world studies; brain metastase; pyrotinib; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITOR; BRAIN METASTASES; CHEMOTHERAPY; TRASTUZUMAB; CISPLATIN;
D O I
10.3389/fphar.2023.1100556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metastatic breast cancer, have been rarely reported. Here, we evaluated the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive metastatic breast cancer (MBC).Methods: This was a prospective, real-world, observational cohort study. Through the Breast Cancer Information Management System, HER-2 positive MBC patients treated with pyrotinib between 2017/06 and 2020/09 were included. Provider-reported objective response rate, progression-free survival (PFS), and overall survival (OS) were considered in the assessment of treatment outcomes. Tumor responses to pyrotinib treatment were calculated using RECIST 1.1. Adverse events were evaluated using clinical records.Results: The trial involved 113 individuals who were receiving pyrotinib treatment, with an average age of 51 years. Complete response, partial response and stable disease were observed in 9 (8.0%), 66 (58.4%), and 17 (15.0%) patients, respectively, while progressive disease was recorded in 20 (17.7%) patients. After a median follow-up of 17.2 months, the median PFS was 14.1. The most common adverse events of any grade were diarrhea (87.6%), vomiting (31.9%), and palmar-plantar erythrodysesthesia (26.6%). Among the patients with brain metastases, the median PFS and OS were 15.2 and 19.8 months, respectively. In addition, pyrotinib has similar efficacy in various subtypes of HER2-positive MBC patients, as shown by the lack of a significant difference of PFS and OS among pyrotinib-treated patients with or without brain metastases, or patients using pyrotinib as first-line, second-line, third-line or beyond therapies.Conclusion: Our real-world results demonstrated equivalent clinical efficacy in HER-2 positive MBC patients compared to phase II and phase III clinical trials with pyrotinib, and promising outcomes in patients with brain metastases.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study
    Qu, Fei
    Lu, Rongrong
    Wu, Xinyu
    Liu, Qian
    Zha, Mengyao
    Li, Huihui
    Yuan, Yuan
    Han, Zhengxiang
    Cai, Dongyan
    Huang, Xiang
    Yin, Yongmei
    Li, Wei
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
    Lin, Ying
    Lin, Mingxi
    Zhang, Jian
    Wang, Biyun
    Tao, Zhonghua
    Du, Yiqun
    Zhang, Sheng
    Cao, Jun
    Wang, Leiping
    Hu, Xichun
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1059 - 1066
  • [33] Efficacy and safety of disitamab vedotin after trastuzumab for HER2-positive breast cancer: A real-world data of retrospective study
    Li, C.
    Yu, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [34] Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real-world study.
    Feng, Jifeng
    Zhang, Lili
    Wu, Xiaohong
    Zhou, Jun
    Zhu, Mingzhen
    Zhang, Yusong
    Yu, Hao
    Han, Zhengxiang
    Guo, Yujiang
    Guan, Xiaoqing
    Wang, Xufen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Real-world incidence and management of diarrhea secondary to pyrotinib in patients with HER-2 positive breast cancer
    Liu, Hong
    Ma, Li
    Wang, Xu
    Chang, Xinzhong
    Yu, Qi
    Huang, Qingfeng
    Hao, Chunfang
    Liu, Jun
    Zhao, Jing
    Li, Shufen
    Tong, Zhongsheng
    Shi, Yehui
    Lu, Ning
    Zhao, Weipeng
    Wang, Tong
    Cao, Xuchen
    Wang, Chen
    Liu, Juntian
    Zhao, Ying
    Zhang, Lina
    Guo, Baoliang
    Wang, Xin
    Di, Xu
    Gao, Chunhui
    Liu, Zongzhan
    Sun, Shuo
    Li, Linwei
    CANCER RESEARCH, 2023, 83 (05)
  • [36] Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer
    Mougalian, S. S.
    Copher, R.
    McAllister, L.
    Radtchenko, J.
    Wang, E. C.
    Broscious, M.
    Yu, H-T
    Kish, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [37] Real-world evidence of Trastuzumab biosimilars in HER2-positive breast cancer: Evaluating utilization, efficacy, and safety in Taiwan
    Lo, Yi-Hung
    Tzeng, Yen-Dun
    CANCER RESEARCH, 2024, 84 (09)
  • [38] Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer
    de Nonneville, Alexandre
    Sabatier, Renaud
    Goncalves, Anthony
    Extra, Jean-Marc
    Tarpin, Carole
    Launay, Simon
    Tassy, Louis
    Viens, Patrice
    Rousseau, Frederique
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (03) : 281 - 283
  • [39] Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
    Gong, Chengcheng
    Zhao, Yannan
    Wang, Biyun
    Hu, Xichun
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    ONCOTARGET, 2017, 8 (35) : 59810 - 59822
  • [40] Real-world treatment in patients with HER2+metastatic breast cancer
    Colomer, R.
    Hall, P.
    Szkultecka-Debek, M.
    Bondi, R. C.
    Flinois, A.
    Auziere, S.
    Le Cleac'h, J. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 197 - 205